XNAS:AEGR Aegerion Pharmaceuticals Inc Insider Activity 4 Filing - 10/15/2012

Effective Date 10/15/2012

XNAS:AEGR Fair Value Estimate
Premium
XNAS:AEGR Consider Buying
Premium
XNAS:AEGR Consider Selling
Premium
XNAS:AEGR Fair Value Uncertainty
Premium
XNAS:AEGR Economic Moat
Premium
XNAS:AEGR Stewardship
Premium
 
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
ALTA BIOPHARMA PARTNERS III LP
  2. Issuer Name and Ticker or Trading Symbol
Aegerion Pharmaceuticals, Inc. [AEGR]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
ONE EMBARCADERO CENTER, SUITE 3700
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2012
(Street)

SAN FRANCISCO, CA 94111
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2012   S   55,626(1) D $17.54(1) 2,408,426 D(2)(3)  
Common Stock 10/16/2012   S   128,229(4) D $18.67(4) 2,280,197 D(2)(3)  
Common Stock 10/15/2012   S   3,736(1) D $17.54(1) 161,742 I(3)(5) See footnote(3)(5)
Common Stock 10/16/2012   S   8,611(4) D $18.67(4) 153,131 I(3)(5) See footnote(3)(5)
Common Stock 10/15/2012   S   1,371(1) D $17.54(1) 59,350 I(3)(6) See footnote(3)(6)
Common Stock 10/16/2012   S   3,160(4) D $18.67(4) 56,190 I(3)(6) See footnote(3)(6)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
ALTA BIOPHARMA PARTNERS III LP
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94111
    X    
PENHOET EDWARD
ONE EMBARCADERO CENTER, SUITE 3700
SAN FRANCISCO, CA 94111
    X    
CHAMPSI FARAH
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94132
    X    
HURWITZ EDWARD
ONE EMBARCADERO CENTER, SUITE 3700
SAN FRANCISCO, CA 94111
    X    
ALTA BIOPHARMA MANAGEMENT III LLC
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94111
    X    
ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94111
    X    
ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94111
    X    
Kiley Alison
ONE EMBARCADERO CENTER
SUITE 3700
SAN FRANCISCO, CA 94111
    X    

Signatures

 by Alta BioPharma Management III, LLC, /s/ Farah Champsi, Director   10/17/2012
** Signature of Reporting Person Date

 /s/ Edward Penhoet   10/17/2012
** Signature of Reporting Person Date

 /s/ Farah Champsi   10/17/2012
** Signature of Reporting Person Date

 /s/ Edward Hurwitz   10/17/2012
** Signature of Reporting Person Date

 /s/ Farah Champsi, Director   10/17/2012
** Signature of Reporting Person Date

 by Alta BioPharma Management III, LLC /s/ Farah Champsi, Director   10/17/2012
** Signature of Reporting Person Date

 /s/ Farah Champsi, Manager   10/17/2012
** Signature of Reporting Person Date

 /s/ Alison Kiley   10/17/2012
** Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) On October 15, 2012, Alta BioPharma Partners III, L.P. ("ABPIII"), Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("ABMPIIIKG"), and Alta Embarcadero BioPharma Partners III, LLC ("AEBPIII") disposed of 55,626, 3,736 and 1,371 shares of the Issuer's Common Stock, respectively, on the public market at an average price of $17.54 per share. The range of sale prices for the transactions reported was $17.20 to $18.08 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares sold at each separate price.
(2) These securities are beneficially owned by ABPIII.
(3) Alta BioPharma Management III, LLC ("ABMIII") is the general Partner of ABPIII, the managing limited partner of ABPIIIKG. Farah Champsi, Edward Penhoet, and Edward Hurwitz are directors of ABMIII and managers of AEBPIII, along with ABPIII and ABPIIIKG shall be known as "the Funds," exercise shared voting and investment power with respect to the securities held by the Funds. Alison Kiley is a member of ABM III. Each of the reporting persons disclaim beneficial ownership of such securities, except to the extend of his, her, or its proportionate pecuniary interest herein.
(4) On October 16, 2012, ABPIII, ABMPIIIKG, and AEBPIII disposed of 128,229, 8,611 and 3,160 shares of the Issuer's Common Stock, respectively, on the public market at an average price of $18.67 per share. The range of sale prices for the transactions reported was $18.20 to $19.23 per share. The reporting persons undertake to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares sold at each separate price.
(5) These securities are beneficially owned by ABPIIIKG.
(6) These securities are beneficially owned by AEBPIII.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

XNAS:AEGR Aegerion Pharmaceuticals Inc Insider Activity 4 Filling

Aegerion Pharmaceuticals Inc XNAS:AEGR Stock - Get Insider Activity SEC Filing of Aegerion Pharmaceuticals Inc XNAS:AEGR stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

Content Partners
XNAS:AEGR Aegerion Pharmaceuticals Inc Insider Activity 4 Filing - 10/15/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XNAS:AEGR Aegerion Pharmaceuticals Inc Insider Activity 4 Filing - 1/30/2012  |  Next: XNAS:AEGR Aegerion Pharmaceuticals Inc Insider Activity 4 Filing - 2/1/2012